Two Cases of Cytomegalovirus Pneumonia after CD34 Selected Autologous Stem Cell Transplantation.
10.5045/kjh.2006.41.2.134
- Author:
Young Lan KWON
1
;
Jae Kwon JOENG
;
Ga Young KIM
;
Sae Rom KIM
;
Se Young LEE
;
Young Deuk YOUN
;
Jung Lim LEE
;
Won Sik LEE
;
Gun Young KWON
;
Jae Hoo PARK
Author Information
1. Department of Internal Medicine, Daegu Fatima Hospital, Korea. JLLEE3@kornet.net
- Publication Type:Case Report
- Keywords:
CMV pneumonia;
CD34 selected stem cell transplantation;
T-cell lymphoblastic lymphoma;
Breast cancer
- MeSH:
Biopsy;
Breast Neoplasms;
Bronchoalveolar Lavage;
Cytomegalovirus*;
Lung;
Mortality;
Pneumonia*;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Stem Cell Transplantation*;
Stem Cells*;
T-Lymphocytes
- From:Korean Journal of Hematology
2006;41(2):134-137
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Cytomegalovirus (CMV) pneumonia is an important cause of treatment related mortality after allogeneic stem cell transplantation (SCT) and autologous SCT, particularly in a CD34 selected setting. There is little known about the immune reconstitution pertaining to the CMV after CD34 selected SCT. However, several studies have suggested there is more profound immunodeficiency early in the CD34 selected population compared with the unselected population. We encountered two fatal cases of CMV pneumonia at the CD34 selected SCT for T-cell lymphoblastic lymphoma and high-risk breast cancer that was confirmed through a lung biopsy and bronchoalveolar lavage. In conclusion, autologous CD34 selected CMV seropositive recipients need to be monitored in a similar manner to allogeneic recipients.
